Summit Therapeutics Statistics
Total Valuation
SMMT has a market cap or net worth of $11.86 billion. The enterprise value is $11.19 billion.
| Market Cap | 11.86B |
| Enterprise Value | 11.19B |
Important Dates
The last earnings date was Thursday, July 23, 2026, after market close.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SMMT has 797.75 million shares outstanding. The number of shares has increased by 4.03% in one year.
| Current Share Class | 797.75M |
| Shares Outstanding | 797.75M |
| Shares Change (YoY) | +4.03% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 76.88% |
| Owned by Institutions (%) | 15.38% |
| Float | 150.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 484.68 |
| PB Ratio | 18.72 |
| P/TBV Ratio | 18.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | 12.79 |
| EV / EBIT | 12.79 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.96, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.96 |
| Quick Ratio | 6.67 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -192.50% and return on invested capital (ROIC) is -119.47%.
| Return on Equity (ROE) | -192.50% |
| Return on Assets (ROA) | -101.61% |
| Return on Invested Capital (ROIC) | -119.47% |
| Return on Capital Employed (ROCE) | 134.88% |
| Weighted Average Cost of Capital (WACC) | -2.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.23M |
| Employee Count | 265 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.12% in the last 52 weeks. The beta is -1.24, so SMMT's price volatility has been lower than the market average.
| Beta (5Y) | -1.24 |
| 52-Week Price Change | -48.12% |
| 50-Day Moving Average | 14.35 |
| 200-Day Moving Average | 16.83 |
| Relative Strength Index (RSI) | 56.65 |
| Average Volume (20 Days) | 3,680,980 |
Short Selling Information
The latest short interest is 37.33 million, so 24.58% of the outstanding shares have been sold short.
| Short Interest | 37.33M |
| Short Previous Month | 39.86M |
| Short % of Shares Out | 24.58% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -874.84M |
| Pretax Income | -856.09M |
| Net Income | -856.09M |
| EBITDA | 875.02M |
| EBIT | 874.84M |
| Earnings Per Share (EPS) | -$1.12 |
Balance Sheet
The company has $690.68 million in cash and $20.38 million in debt, with a net cash position of $670.29 million or $0.84 per share.
| Cash & Cash Equivalents | 690.68M |
| Total Debt | 20.38M |
| Net Cash | 670.29M |
| Net Cash Per Share | $0.84 |
| Equity (Book Value) | 629.98M |
| Book Value Per Share | 0.79 |
| Working Capital | 617.01M |
Cash Flow
In the last 12 months, operating cash flow was -$458.43 million and capital expenditures -$1.39 million, giving a free cash flow of -$459.82 million.
| Operating Cash Flow | -458.43M |
| Capital Expenditures | -1.39M |
| Depreciation & Amortization | 174,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -459.82M |
| FCF Per Share | -$0.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SMMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.03% |
| Shareholder Yield | -4.03% |
| Earnings Yield | -7.22% |
| FCF Yield | -3.88% |
Analyst Forecast
The average price target for SMMT is $28.34, which is 90.59% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.34 |
| Price Target Difference | 90.59% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |